Disc Medicine (NASDAQ:IRON) Given New $73.00 Price Target at Stifel Nicolaus

Disc Medicine (NASDAQ:IRON - Free Report) had its price objective upped by Stifel Nicolaus from $71.00 to $73.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also recently issued reports on the stock. HC Wainwright reissued a buy rating and set a $70.00 target price on shares of Disc Medicine in a report on Monday, April 1st. BMO Capital Markets reduced their price objective on Disc Medicine from $80.00 to $50.00 and set an outperform rating for the company in a research note on Tuesday, April 2nd. Cantor Fitzgerald restated an overweight rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Wednesday, December 20th. Raymond James reiterated an outperform rating and set a $40.00 price target (down from $75.00) on shares of Disc Medicine in a research report on Monday, April 1st. Finally, Morgan Stanley decreased their price target on Disc Medicine from $75.00 to $40.00 and set an equal weight rating for the company in a report on Tuesday, April 2nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $57.29.

Disc Medicine Stock Up 5.6 %

Shares of NASDAQ:IRON traded up $1.68 during trading on Monday, hitting $31.78. The stock had a trading volume of 504,613 shares, compared to its average volume of 424,616. Disc Medicine has a 12-month low of $20.88 and a 12-month high of $77.60. The stock has a market capitalization of $767.17 million, a price-to-earnings ratio of -8.65 and a beta of 0.18. The stock has a 50-day simple moving average of $62.17 and a two-hundred day simple moving average of $56.57.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22). As a group, sell-side analysts forecast that Disc Medicine will post -4.44 earnings per share for the current year.

Insider Buying and Selling at Disc Medicine

In related news, Director Kevin Bitterman sold 20,000 shares of Disc Medicine stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $64.00, for a total value of $1,280,000.00. Following the sale, the director now owns 786,160 shares of the company's stock, valued at approximately $50,314,240. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Kevin Bitterman sold 20,000 shares of the company's stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $64.00, for a total transaction of $1,280,000.00. Following the completion of the transaction, the director now owns 786,160 shares in the company, valued at approximately $50,314,240. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Venture Fund X. L.P. Atlas sold 30,000 shares of the firm's stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $64.00, for a total transaction of $1,920,000.00. Following the completion of the transaction, the insider now directly owns 1,449,686 shares in the company, valued at $92,779,904. The disclosure for this sale can be found here. Over the last three months, insiders have sold 200,000 shares of company stock valued at $13,347,500. Company insiders own 4.71% of the company's stock.

Institutional Trading of Disc Medicine

Several large investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its position in Disc Medicine by 149.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,000 shares of the company's stock worth $578,000 after acquiring an additional 5,990 shares during the last quarter. Vanguard Group Inc. lifted its stake in Disc Medicine by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 764,544 shares of the company's stock worth $44,160,000 after purchasing an additional 99,092 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Disc Medicine by 224.6% during the 4th quarter. Wellington Management Group LLP now owns 177,726 shares of the company's stock worth $10,265,000 after purchasing an additional 122,981 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Disc Medicine by 127.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 62,175 shares of the company's stock valued at $3,591,000 after purchasing an additional 34,821 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $797,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.